Table 3.
Summary of nanotechnology-empowered therapeutics in HD
| Drug | Type of NPs | NPs material | BBB penetration targeting | Application model | Route of administration | Ref. |
|---|---|---|---|---|---|---|
| Anti-HTT siRNA | Chitosan | Chitosan | NA | Transgenic YAC128 HD mice | Intranasal | (Sava et al., 2020) |
| hsiRNAHTT | Exosome | U87 glioblastoma cells exosome | NA | Rats | Intrastriatal bolus | (Didiot et al., 2016) |
| GPx-like Activity | Biocompatible nanoscale | C-Mn3O4 | NA | 3-NPA induced HD mice | Intraperitoneal | (Adhikari et al., 2021) |
| Selenium nanoparticles | Selenium | Nano selenium | NA | Transgenic HD models of Caenorhabditis elegans | NA | (Cong et al., 2019) |
| Rosmarinic acid | Solid lipid | Glycerol monostearate (GMS), HSPC, Tween 80, soya Lecithin | NA | 3-NPA induced HD rats | Intranasal | (Bhatt et al., 2015) |
| Thymoquinone | Solid lipid | Stearic acid, lecithin, taurocholate | NA | 3-NPA induced HD rats | Intraperitoneal | (Ramachandran & Thangarajan, 2018) |
| Epigallocatechin-3-gallate (EGCG) | Polymer | PEG-PLGA | NA | 3-NPA induced HD mice | Intraperitoneal | (Cano et al., 2021) |
| Colesterol | Polymer | PLGA | Heptapeptide (g7) | Transgenic R6/2 HD mice | Intraperitoneal | (Birolini et al., 2021) |
| Colesterol fluorescente (NBDchol) | Polymer | PLGA conjugated rhodamine | Glycopeptides (g7) | Transgenic R6/2 HD mice | Intraperitoneal | (Valenza et al., 2015) |
| Ivabradine | Phospholipids | Phospholipon 90H | NA | 3-nitropropionic acid (3-NPA) induced HD mice | Intravenous | (Saad et al., 2021) |